Doravirine/Islatravir

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameDoravirine/Islatravir
Drug Alias NameIslatravir/doravirineDOR/ISLIDVYNSOMK-8591A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionNucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitorsNon-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2026/03/06
Country/TerritoryCanadaUnited StatesTaiwan +[26] 
CombinationsYes DoravirineIslatravir
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme LLCMsd Kk
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A